Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses.

PloS one - 8 Oct 2010

A Jiye, Qian Sixuan, Wang Guangji, Yan Bei, Zhang Sujiang, Huang Qing, Ni Lingna, Zha Weibin, Liu Linsheng, Cao Bei, Hong Ming, Wu Hanxin, Lu Hua, Shi Jian, Li Mengjie, Li Jianyong

Abstract excerpt

The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure. Metabonomic and genomic profiling of patients' responses to drug interventions can provide nove...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gas Chromatography-Mass Spectrometry

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 20949032
DOI: 10.1371/journal.pone.0013186
PMCID: PMC2951899

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20949032-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses.PMID 20949032Read ↗

Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemiaSemantic proximity Read ↗

Identification of glucuronic acid as a biomarker of poor prognosis in acute myeloid leukemia based on plasma metabolomicsSemantic proximity Read ↗

Detection of Resistance to Imatinib by Metabolic ProfilingSemantic proximity Read ↗

Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy.Semantic proximity Read ↗

NMR-Based Metabolomic Analysis of the Molecular Pathogenesis of Therapy-Related Myelodysplasia/Acute Myeloid LeukemiaSemantic proximity Read ↗

In vivo metabolomic study uncovers distinct metabolic phenotypes of host tissues and predicts oxidative state of acute myeloid leukemiaSemantic proximity Read ↗

Bidirectional interplay between metabolism and epigenetics in hematopoietic stem cells and leukemiaSemantic proximity Read ↗

The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker.Semantic proximity Read ↗

Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targetsSemantic proximity Read ↗

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.Semantic proximity Read ↗

Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A reviewSemantic proximity Read ↗

Multiomics Integration Elucidates Metabolic Modulators of Drug Resistance in LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.